Organosilane for Surface Cleaning in Intensive Care Units
Launched by HOSPITAL ISRAELITA ALBERT EINSTEIN · Jan 5, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a cleaning method in intensive care units (ICUs) to see if using a special disinfectant called organosilane, along with regular cleaning practices, can help reduce the number of infections that patients might get while in the hospital. The goal is to find out if this new cleaning approach is more effective than traditional cleaning alone in preventing healthcare-associated infections (HAIs).
To participate in this trial, you must be at least 18 years old and admitted to one of the participating ICUs. Unfortunately, patients under 18 or those in ICUs that already use organosilane products for cleaning cannot join. If you are eligible and choose to participate, you can expect to receive care in an ICU where they are testing this new cleaning method. It’s important to know that the study is currently recruiting participants, and your involvement could help improve safety for future patients in hospital settings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients aged 18 years and older who will be admitted to the participating ICUs
- Exclusion Criteria:
- • Patients under 18 years
- • ICUs that may use any organosilane formulation for surface disinfection
About Hospital Israelita Albert Einstein
Hospital Israelita Albert Einstein is a leading healthcare institution in Brazil, renowned for its commitment to excellence in patient care, education, and research. As a prominent clinical trial sponsor, the hospital emphasizes innovation and scientific advancement, facilitating cutting-edge studies across various medical disciplines. With a state-of-the-art infrastructure and a dedicated team of professionals, Hospital Israelita Albert Einstein fosters collaboration with global research networks to enhance clinical outcomes and contribute to the advancement of medical knowledge. The institution is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brasília, , Brazil
São Paulo, , Brazil
Brasília, , Brazil
São Paulo, , Brazil
Porto Alegre, , Brazil
São Paulo, , Brazil
São Paulo, , Brazil
Belém, , Brazil
Fortaleza, , Brazil
Olinda, , Brazil
Pelotas, , Brazil
Salvador, , Brazil
Santa Cruz Do Sul, , Brazil
São Luís, , Brazil
Belo Horizonte, , Brazil
Goiânia, , Brazil
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials